Awesome.
After 6 weeks (day 43) treatment with PD1-Vaxx, one patient’s tumor was non-measurable indicating a complete response (CR), with three patients showing stabilization of disease (SD) and a single patient progressing (PD). The status of two patients from cohort 1 (1 x SD, 1 x CR) were unchanged at day 85.
These are encouraging results in patients who have progressed after previous treatment with checkpoint inhibitors including Keytruda®, Opdivo® or Tecentriq®. Further results and scans are scheduled over the coming weeks. The clinical results indicate that PD1-Vaxx is showing early signs of an immune responses in patients, with antibodies to the target biomarker PD1 evident in validated assays.
Imugene MD & CEO Leslie Chong said “Phase 1 trials are generally designed to look for safety, tolerability and early response signals to determine the optimal dose for further development. I am encouraged that we are seeing positive signals at such an early stage of our PD1-Vaxx Phase I trial”.
- Forums
- ASX - By Stock
- IMU
- Ann: Final Highest Dose in Phase 1 Clinical Trial of PD-VAXX
Ann: Final Highest Dose in Phase 1 Clinical Trial of PD-VAXX, page-3
-
- There are more pages in this discussion • 263 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IMU (ASX) to my watchlist
|
|||||
Last
6.0¢ |
Change
0.004(7.14%) |
Mkt cap ! $440.9M |
Open | High | Low | Value | Volume |
5.7¢ | 6.0¢ | 5.6¢ | $546.8K | 9.385M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
18 | 749965 | 5.9¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
6.0¢ | 2438722 | 26 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
20 | 1083752 | 0.059 |
22 | 1343480 | 0.058 |
15 | 2453848 | 0.057 |
16 | 1262690 | 0.056 |
22 | 4944717 | 0.055 |
Price($) | Vol. | No. |
---|---|---|
0.060 | 2461698 | 26 |
0.061 | 1147679 | 11 |
0.062 | 831538 | 6 |
0.063 | 231315 | 4 |
0.064 | 483393 | 5 |
Last trade - 13.45pm 23/07/2024 (20 minute delay) ? |
Featured News
IMU (ASX) Chart |
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO & MD
Charles Armstrong
CEO & MD
Previous Video
Next Video
SPONSORED BY The Market Online